ArticleNeurogastroenterology and motility2022
Functional gastrointestinal and somatoform symptoms five months after SARS-CoV-2 infection: A controlled cohort study.
Article in Neurogastroenterology and motility, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 10 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025Pooled it
- Post-infection irritable bowel syndrome following Coronavirus disease-19: A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Pooled it
- The global prevalence of depression, anxiety, and sleep disorder among patients coping with Post COVID-19 syndrome (long COVID): a systematic review and meta-analysis.BMC psychiatry · 2024Pooled it
- Risk of long COVID main symptoms after SARS-CoV-2 infection: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Pooled it
- Pooled it
- Taste loss as a distinct symptom of COVID-19: a systematic review and meta-analysis.Chemical senses · 2023Pooled it
- Comparison of Long COVID-19 Caused by Different SARS-CoV-2 Strains: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Psychiatric and neuropsychiatric sequelae of COVID-19 - A systematic review.Brain, behavior, and immunity · 2021Pooled it
- Pooled it
- Psychological and Clinical Factors Mediate Post-COVID-19 Irritable Bowel Syndrome.Neurogastroenterology and motility · 2026Article
- The effect of COVID-19 and socioeconomic inequalities on emergency department accesses for psychiatric conditions.PloS one · 2026Article
- Impairment of Esophageal Barrier Integrity: New Insights into Esophageal Symptoms in Post-COVID-19.Digestive diseases and sciences · 2025Article
- Digestive Manifestations of Post-COVID-19: A Focus on Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2025Review
- Case Report: Celiac plexus block improves gastrointestinal Long COVID symptoms.Frontiers in neuroscience · 2025Article
- The Silent Syndrome of Long COVID and Gaps in Scientific Knowledge: A Narrative Review.Viruses · 2024Review
- A Population-Based Outcome-Wide Association Study of the Comorbidities and Sequelae Following COVID-19 Infection.Journal of epidemiology and global health · 2023Article
- Neurological Consequences, Mental Health, Physical Care, and Appropriate Nutrition in Long-COVID-19.Cellular and molecular neurobiology · 2023Review
- Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review.World journal of gastroenterology · 2023Review
- Association between somatic symptom disorder and symptoms with daily life impairment after SARS-CoV-2 infection - results from a population-based cross-sectional study.Journal of psychosomatic research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal infections represent a risk factor for functional gastrointestinal and somatoform extraintestinal disorders. We investigated the prevalence and relative risk (RR) of gastrointestinal and somatoform symptoms 5 months after SARS-CoV-2 infection compared with a control cohort.
methodsOne hundred and sixty-four SARS-CoV-2 infected patients and 183 controls responded to an online questionnaire about symptoms and signs during the acute phase of the infection and after 4.8 ± 0.3 months. Presence and severity of gastrointestinal symptoms, somatization, anxiety, and depression were recorded with standardized questionnaires. Stool form and presence of irritable bowel syndrome (IBS) were also recorded. Any association between exposure to infection and symptoms was evaluated by calculating crude and adjusted RR values and score differences with 95% confidence intervals (CI). KEY
resultsFever, dyspnea, loss of smell/taste/weight, diarrhea, myalgia, arthralgia, and asthenia were reported by more than 40% of patients during the acute phase. Compared with controls, adjusted RRs for loose stools, chronic fatigue, and somatization were increased after infection: 1.88 (95% CI 0.99-3.54), 2.24 (95% CI 1.48-3.37), and 3.62 (95% CI 1.01-6.23), respectively. Gastrointestinal sequelae were greater in patients with diarrhea during the acute phase. CONCLUSIONS & INFERENCES: Mild gastroenterological symptoms persist 5 months after SARS-CoV-2 infection, in particular in patients reporting diarrhea in the acute phase. Infected patients are at increased risk of chronic fatigue and somatoform disorders, thus supporting the hypothesis that both functional gastrointestinal and somatoform disorders may have a common biological origin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.